| Combination chemotherapy with topotecan for non-small cell lung cancer. | |
| | |
MedLine Citation:
|
PMID: 14565511 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Patients with non-small cell lung cancer (NSCLC) typically receive platinum-based combination chemotherapy. In spite of improvements in symptoms and survival, response rates remain low and newer agents are being investigated. The newer agents may offer increased efficacy and reduced toxicity compared with established agents and regimens. The topoisomerase-I inhibitor, topotecan, achieves single-agent response rates of 4-25% in NSCLC. Topotecan has also been studied in combinations: a combination of topotecan, administered using the standard 5-day schedule, with cisplatin was effective but was associated with myelosuppression. The combination of topotecan plus carboplatin may be better tolerated and warrants further investigation. Topotecan was also combined with newer agents (gemcitabine, vinorelbine, docetaxel, paclitaxel) using a range of different administration schedules of topotecan. Response rates of up to 30% were achieved. A weekly schedule of topotecan was effective and well tolerated and was also convenient for healthcare professionals and patients. |
| | |
Authors:
|
Afshin Dowlati; Nathan Levitan |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Lung cancer (Amsterdam, Netherlands) Volume: 41 Suppl 4 ISSN: 0169-5002 ISO Abbreviation: Lung Cancer Publication Date: 2003 Aug |
Date Detail:
|
Created Date: 2003-10-20 Completed Date: 2003-12-10 Revised Date: 2013-06-03 |
Medline Journal Info:
|
Nlm Unique ID: 8800805 Medline TA: Lung Cancer Country: Ireland |
Other Details:
|
Languages: eng Pagination: S23-6 Citation Subset: IM |
Affiliation:
|
Division of Hematology/Oncology, Case Western Reserve University and University Hospitals of Cleveland, Ohio, USA. axd44@po.cwru.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Combined Chemotherapy Protocols
/
therapeutic use* Carboplatin / administration & dosage Carcinoma, Non-Small-Cell Lung / drug therapy* Cisplatin / administration & dosage Deoxycytidine / administration & dosage, analogs & derivatives* Humans Lung Neoplasms / drug therapy* Paclitaxel / administration & dosage Topoisomerase I Inhibitors Topoisomerase II Inhibitors Topotecan / administration & dosage, therapeutic use* Vinblastine / administration & dosage, analogs & derivatives* |
| Chemical | |
Reg. No./Substance:
|
0/Topoisomerase I Inhibitors; 0/Topoisomerase II Inhibitors; 123948-87-8/Topotecan; 15663-27-1/Cisplatin; 33069-62-4/Paclitaxel; 41575-94-4/Carboplatin; 865-21-4/Vinblastine; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine; Q6C979R91Y/vinorelbine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Single-agent chemotherapy for non-small cell lung cancer.
Next Document: Weekly topotecan in the management of lung cancer.